by Charles Bankhead
TAMPA, Fla. — About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial showed.
Overall, 23% of 48 patients had partial responses, increasing to 26% in those who had baseline and confirmatory CT scans. Almost 80% obtained clinical benefit. Median duration of response was 19.1 months.
Aside from decreased neutrophil count, grade 3+ adverse events (AEs) were uncommon, reported Brian Slomovitz, MD, of Mount Sinai Medical Center in Miami, at the Society of Gynecologic Oncologyopens in a new tab or window meeting.
Society of Gynecologic Oncology
Source Reference: Slomovitz BW, et al “GOG 3026 a phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum (LGSOC): A GOG Foundation study” SGO 2023; Abstract 14.
This article was published by Med Page Today.